

# Index

## A

Allosteric inhibitors, 29, 53, 69, 87, 110, 111  
Aneuploidy, 92–93, 108, 120–122, 127,  
139–141, 143, 179, 180, 184, 204, 210,  
233, 234, 238, 260  
Antimitotic, 28, 68, 70, 93, 95, 164, 184, 236  
ARRY-520, 41–43, 48, 68–72, 261  
ATPase, 4–6, 8, 13, 15, 46, 53–54, 91, 94,  
110, 126, 137, 149–151, 166, 184,  
194, 207  
Axon, 153, 201, 209, 252–260  
AZ82, 110, 112

## B

Bipolar spindle assembly, 77–85, 119, 123,  
166, 226  
BTB-1, 14, 184, 185

## C

Cancer, 12, 28, 63, 83, 87, 105, 117–129,  
135–144, 149–167, 174, 200, 223–240,  
251–262  
Cancer signature, 159, 183  
Cell nucleus, 104  
Centrosome(s), 102–105, 118, 120, 123, 124,  
139, 223–226, 228–231, 234, 257  
clustering, 12, 106–111  
separation, 77–84  
Chemosensitivity, 161, 163  
Chemotherapy, 29, 43, 70, 95–96, 107, 122,  
126, 143, 161–164, 223–240, 251, 252,  
256, 260, 261  
Chromokinesin, 13, 87, 135–144, 260

Chromosome architecture, 138  
Chromosome congression, 11, 87, 137, 151,  
152, 174, 176, 180, 196  
Clinical trials, 11, 12, 29, 30, 34, 40, 42,  
44, 47, 48, 63–73, 94, 111, 126,  
184, 206, 209, 228, 236, 238, 239,  
253, 257, 261  
CW069, 110–112  
Cytokinesis, 13–15, 80, 92, 93, 103, 135–137,  
139, 144, 149–153, 162–164, 166,  
193–208, 210, 224, 238, 256, 260

## D

Declustering, 110  
Dendrite, 201, 202, 252–259  
Drug discovery, 47–49, 167, 239  
Drug resistance, 84, 107, 109, 118, 238

## E

Eg5, 7–11, 27–49, 53–61, 63, 64, 67–72, 77,  
78, 80–85, 101, 103, 126, 166, 184,  
185, 228, 230, 234, 257  
Eg5-independent cells (EICs), 81, 83, 84

## G

Genome stability, 139, 140, 142, 143

## H

HSET inhibitor, 109–112  
Human spleen, embryo, and testes protein  
(HSET), 12, 101–112

**I**

Inhibitor, 6, 10–14, 27–49, 53–61, 63–73, 84, 85, 91, 92, 94–96, 107, 110, 111, 117, 124–129, 143, 163, 166, 167, 175, 184–185, 205, 228, 230, 236–240, 251–262  
 Ispinesib, 29–32, 34, 46, 48, 67–70, 261

**K**

Kif2a, 8, 12, 46, 117–121, 123–126, 129, 203, 260  
 Kif2b, 12, 117–120, 122, 123, 125, 126, 180  
 Kif2c, 8, 12, 13, 117, 118, 120  
 KifC1, 12, 46, 101–112  
 KIF14, 15, 149–167  
 Kif15, 11, 48, 77–85, 141, 166, 257  
 Kif19, 14, 172, 173, 175, 176, 178  
 Kif18A, 14, 89, 172–176, 178–185  
 Kif18B, 14, 172–176, 179, 181  
 Kinesin-5, 4, 6–12, 59, 77, 80, 81, 101, 238, 257–259, 261  
 Kinesin-8, 6–8, 14, 171–185  
 Kinesin-12, 7–9, 11, 78–80, 85, 257–261  
 Kinesin(s), 1–15, 28, 29, 53, 63–73, 77–85, 87, 101–112, 117–129, 135–144, 149–167, 171–185, 193–210, 230, 251–262  
 Kinesin-6 family, 14, 193–198, 209, 210  
 Kinesin motor domain, 1, 3–6, 15, 79, 136, 137, 149–151, 166, 173  
 Kinetochores(s), 9, 11, 82–83, 87–92, 102, 105, 118–125, 127, 143, 173, 176, 178, 180, 181, 223–227, 229, 231–234

**L**

Lead optimisation, 29, 34–36, 40–44, 47, 48

**M**

MAPs. *See* Microtubule-associated-proteins (MAPs)  
 MCAK. *See* Mitotic centromere associated kinesin (MCAK)  
 Mechanochemistry, 3, 4, 6, 54  
 Microtubule  
   depolymeriser, 6, 88, 93, 117–129, 178, 181, 232, 254, 260  
   detachment, 120, 123–125, 128  
   dynamics, 13, 14, 82–83, 89–91, 93, 123, 129, 171–173, 178–180, 196, 204, 206, 223, 225–227, 230–231, 234, 235, 239  
   fragments, 124, 127, 128  
 Microtubule-associated-proteins (MAPs), 9, 77, 78, 84, 105, 180, 230–232, 234

Mitosis, 1, 3, 8, 13–15, 29, 43, 48, 63, 70, 71, 77, 81, 82, 84, 85, 92, 93, 95, 102, 103, 105, 106, 108, 110, 117–124, 127, 135–140, 142–144, 151, 173, 174, 176, 177, 180–182, 185, 194–196, 202, 207–210, 223, 225–235, 237–239, 251–253, 256, 257, 260  
 Mitotic centromere associated kinesin (MCAK), 8, 12–13, 29, 46, 117–129, 166, 181, 228, 230, 232–234  
 Mitotic kinesin, 1, 3, 6, 8–10, 28, 63–73, 94, 135, 141, 143, 149, 159, 164, 184, 251–262  
 Mitotic kinesin-like protein 1 (MKLP1), 7, 14, 153, 193–210, 228, 235, 257  
 Mitotic kinesin-like protein 2 (MKLP2), 14, 193–210  
 Mitotic spindle, 29, 30, 46, 63, 70, 89–91, 102–103, 105, 106, 118, 124, 128, 137, 138, 143, 151, 153, 174, 176, 184, 196, 205, 206, 223, 225, 227–229, 234, 238, 253  
 MKLP1. *See* Mitotic kinesin-like protein 1 (MKLP1)  
 MKLP2. *See* Mitotic kinesin-like protein 2 (MKLP2)  
 Monastrol, 185  
   mechanism, 28, 29, 46, 59, 63, 261  
   site, 28, 29, 36, 43  
 Motor, 1, 53, 54, 63, 77, 78, 87, 88, 101–112, 117, 135, 149, 173, 193, 223, 252  
 M-phase phosphoprotein 1 (MPP1), 14, 193–210  
 Myeloma, 42, 48, 68, 69, 71, 72, 94, 95, 140, 201

**N**

Neck linker, 4, 5, 7, 54, 55, 58, 126, 172, 193, 194, 197, 203  
 Neuron, 63, 72, 153, 194, 201, 202, 208, 209, 251–262  
 Non-motor protein, 7, 78, 223–240

**O**

Oncogene, 64, 65, 70, 141–142, 155–162, 164–165, 208  
   addiction, 64, 67, 71

**P**

Paclitaxel, 29, 40, 123–125, 127, 128, 185, 236–239  
 Passenger protein, 205, 228, 233, 238

Pharmacokinetics (PK), 34, 36, 39, 40, 43, 48, 65, 67, 68, 111, 238  
Processive, 3, 4, 6, 7, 88, 171, 177, 194, 195, 197, 232  
Prognostic factor, 160, 182  
Protein kinase, 224, 225, 227–237, 239, 240

**R**

Replication, 48, 140, 142, 143, 165  
Retinoblastoma, 15, 150, 154–158, 160, 164, 166, 176

**S**

Spindle  
assembly, 9, 11–13, 48, 78–80, 85, 91, 93, 102, 105, 109, 120, 122, 129, 137, 180, 181, 196, 197, 203, 223, 226–230  
pole, 9, 78, 80, 87, 102, 104, 105, 108, 109, 118–120, 123–125, 127, 128, 135, 137, 223–227, 231, 234

Switch 1 (Sw1), 4–6, 54, 55, 57–60  
Switch 2 (Sw2), 4–6, 54, 55, 57  
Synthetic lethality, 65

**T**

Targeting protein for Xklp2 (TPX2), 8, 78, 79, 81, 82, 85, 224, 226, 228, 233, 234  
Taxol, 88, 178, 252–256  
Theranostic target, 111  
Therapeutics, 6, 11–15, 29, 32, 36, 39, 48, 49, 63–65, 70, 73, 108–112, 124, 143, 144, 155, 160, 162–167, 171–185, 201, 202, 205, 207, 209, 210, 234, 239, 252  
Toxicity, 32, 36, 40, 63, 65–70, 72, 111, 143, 166  
TPX2. *See* Targeting protein for Xklp2 (TPX2)

**X**

Xklp2, 8, 78–80, 224, 234